One of the issues that is apparently being discussed and potentially could arise under the new TPP is the possibility that there could be restrictions on the formularies that, in our case, the provinces have. As you know, in the U.S., under Medicare Part D, they're not allowed to use their bulk purchasing to actually negotiate lower prices with the drug industry. That is U.S. practice, and I think they are trying to incorporate something somewhat similar into the TPP, which would mean some significant restrictions for us in terms of essentially getting a better deal on behalf of patients. That is certainly one area that is quite important.
Remind me of the second part of your question.